Remove 2024 Remove Prescription Remove Side effects
article thumbnail

Despite benefits, long-acting injectables remain underutilised for schizophrenia

Pharmaceutical Technology

Prescription of daily oral aripiprazole continues to dominate the use of Otsuka and Lundbeck’s once-monthly LAI formulation Abilify Maintena and Alkermes’ Aristada, which can be administered every six weeks. GlobalData forecasts that it will launch in the US and 5EU next year.

article thumbnail

Innovating allergy drug delivery with a needle-free alternative

European Pharmaceutical Review

In August 2024, the European Commission approved EURneffy (adrenaline nasal spray) in the EU as the first needle-free emergency option to treat anaphylaxis. Poster Presented at the 2024 AAAAI Annual meeting, DC, US. This decision was granted a couple of weeks following approval by the US and Drug Administration (FDA).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Engaging Patients in More Moments Along Their Care Journey

PM360

Phreesia research shows that 25% of patients do not have a good understanding of the next steps around their prescription medications, and 29% aren’t sure how to manage their medical condition immediately following a healthcare visit.

article thumbnail

Key Developments from AMCP 2023 on Blockbuster Generics, Diabetes Drugs, PBM Legislation, and More

PM360

A generic here will improve access in OAB to a product with less side effects, which is especially important in the elderly population, Casberg noted. This product would be a more potent prescription version than the OTCs, Casberg notes. In 2024, ARPA removes the 100% AMP cap.

article thumbnail

Oncology Commercial Strategy: Broader Is Better

PM360

But commercializing an oncology product in 2024 means identifying and linking to an authentic shortfall in the lived experience of a patient with cancer, not just a perceived gap in the market. Serious” side effects? Until recently, commercialization of an oncology product was similar to any other pharmaceutical launch.

article thumbnail

Research That Reflects Reality

PM360

The barriers patients experience in accessing treatment: The journey to therapy can go well beyond a doctor’s appointment and a prescription. Insurers may require prior authorization or step therapy before approving the preferred prescription. Patients may need to travel to specialists or undergo pre-treatment tests.

article thumbnail

Elevating Patient Experiences by Breaking Down Internal Silos

PM360

They become supportive extensions of the brand that work on a personalized level with patients and care teams, from the moment the prescription is written to other important points along the treatment journey. Even straightforward interactions like the initial prescription can be cluttered with unnecessary overlap and misalignment.